October 2013 Blog Posts (6)

Researchers Increase Survival in Mice with Glioblastoma by Silencing a Troublesome Oncogene

Glioblastoma multiform or  GBM, the brain cancer that killed Senator Edward M. Kennedy of Massachusetts and kills approximately 13,000 Americans a year, is aggressive and incurable. Now a team of researchers at Northwestern University (Evanston, Illinois) is the team first to demonstrate delivery of a drug that turns off a critical gene in this complex cancer, increasing survival rates significantly in…


Added by Peter Hofland, PhD on October 30, 2013 at 10:30pm — No Comments

Phase I Trial of Novel Antibody-drug Conjugate SGN-LIV1A Initiated in LIV-1-Positive Metastatic Breast Cancer

A new phase I clinical trial was initiated late October 2013 to evaluate SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer. SGN-LIV1A is based on Seattle Genetics’ antibody-drug conjugate (ADC) technology. The trial is designed to assess the safety and antitumor activity of SGN-LIV1A, an ADC targeted to zinc transporter LIV-1 (SLC39A6 or ZIP6), an estrogen regulated protein which is expressed in most subtypes of metastatic breast cancer.*  [1][2]

In the…


Added by Editorial Team on October 23, 2013 at 8:30pm — No Comments

New Recommendations for Clinical Trial Accrual Address Multiple Barriers for Patients and Physicians

New recommendations for overcoming issues related to cancer clinical trial accrual have been published online in the October 29 issue of Journal of Oncology Practice. Following a National Cancer Institute (NCI) and American Society of Clinical Oncology (ASCO) co-sponsored symposium, the research team compiled a summary of best practices and strategies for future research aimed at…


Added by Editorial Team on October 21, 2013 at 10:30am — No Comments

Preliminary Trial Results Suggest Genomic Testing may Allow Many Patients with Early Breast Cancer to Safely Avoid Chemotherapy

Genomic testing,a type of medical test that identifies changes in chromosomes, genes, or proteins, could allow many patients with early breast cancer to safely avoid chemotherapy. This is the preliminary conclusion from a new trial, reported in Amsterdam, The Netherlands, at the European Cancer Congress 2013 this week. [1] The results illustrate that more research is urgently needed to compare and validate the growing number of genomic tests becoming available in oncology.…


Added by Editorial Team on October 1, 2013 at 8:00pm — No Comments

Aggressive form Breast Cancer in Women of Mexican Descent may be Linked to Lactation - Occurs Despite Seemingly Protective Factors

A multitude of medical studies have shown that a woman’s risk of developing breast cancer is directly related to her exposure to endogenous estrogen and progesterone, hormones that are produced by her ovaries. These ovarian hormones stimulate cell growth. Reproductive factors that increase the duration and/or levels of exposure to these hormones, include early onset of menstruation, late onset of menopause, later age at first pregnancy, and never having given birth have been associated…


Added by Editorial Team on October 1, 2013 at 12:00pm — No Comments

Large Variations in Post-surgery Death Rates for Esophageal and Gastric Cancers Leads to European Initiative to Improve Outcomes

A pilot study has shown large variations between European countries in patient survival after surgery for esophageal and gastric cancers. The data presented by Dutch researchers at the 2013 European Cancer Congress (ECC2013)[1] shows that the reasons for these differences are not clear and cannot be explained simply in terms of the volume of patients treated at each hospital.…


Added by Editorial Team on October 1, 2013 at 9:00am — No Comments

Monthly Archives














Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+